Nektar Therapeutics' experimental alopecia areata drug, rezpegaldesleukin, has demonstrated a "deepening" treatment response in patients who previously showed substantial hair regrowth. The new data comes from an extension study of the company's clinical trial, extending a comeback bid that has already caused the firm's shares to skyrocket over the past year.
Patients who had achieved significant hair regrowth during the initial phase of the trial showed continued improvement in the extension period. The treatment response deepened, suggesting the therapy's benefits may strengthen over time rather than plateau.
The extension study results build on earlier positive data that has fueled investor optimism. Nektar's stock has surged dramatically over the last twelve months as clinical progress for the alopecia treatment has unfolded.
The company's shares surged again following the release of these latest results. The promising data extends what has become a remarkable turnaround story for Nektar, positioning rezpegaldesleukin as a potentially significant contender in the alopecia treatment market.
While the extension study shows encouraging durability of response, the drug remains in clinical development and has not yet received regulatory approval. The deepening effect observed suggests the treatment may offer progressive benefits, but larger and longer-term studies will be needed to confirm these findings.